SCHEMBL15924151

SCHEMBL15924151

Cc1cccc(-c2nc3c(c(=O)[nH]c(=O)n3C)n2Cc2ccc(F)c(C(F)(F)F)c2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.51
HSD17B10 Q99714 2/20 0.51
KMT2A Q03164 2/20 0.51
MEN1 O00255 1/20 0.51
HTT P42858 1/20 0.51
ALDH1A1 P00352 4/20 0.51
TSHR P16473 2/20 0.51
ALOX15 P16050 1/20 0.51
HPGD P15428 3/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
GAA P10253 1/20 0.49
MDM2 Q00987 1/20 0.48
KDR P35968 1/20 0.48
USP2 O75604 1/20 0.47
ATM Q13315 1/20 0.47
APOBEC3G Q9HC16 1/20 0.47
KDM4E B2RXH2 1/20 0.47
KDM1A O60341 1/20 0.47
IDO1 P14902 1/20 0.47
POLB P06746 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15924451 0.87 KMT2A (0.58) TP53HSD17B10KMT2AMEN1HTT
SCHEMBL15923446 0.83 ALDH1A1 (0.61) TP53KMT2AMEN1ALDH1A1TSHR
SCHEMBL15922124 0.74 MDM2 (0.55) MDM2
SCHEMBL16363970 0.70 ATM (0.55) TP53HSD17B10KMT2AMEN1ALDH1A1
SCHEMBL15923584 0.69 ATM (0.46) TP53HSD17B10KMT2AMEN1HTT
SCHEMBL5073403 0.69 DPP4 (0.79) TP53HSD17B10KMT2AMEN1HTT
SCHEMBL22800983 0.68 ALDH1A1 (0.66) TP53HSD17B10KMT2AMEN1HTT
SCHEMBL19375412 0.68 ATM (0.71) TP53HSD17B10KMT2AMEN1ALDH1A1
SCHEMBL17845823 0.68 KDM4E (0.56) KMT2AMEN1HTTALDH1A1HPGD
SCHEMBL22738096 0.68 HPGD (0.46) HSD17B10KMT2AMEN1HTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2951180-B1 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS MERCK SHARP & DOHME (US) 2018-05-02 EP disclosed
US-9540377-B2 2,6,7,8 substituted purines as HDM2 inhibitors MERCK SHARP & DOHME CORP. (US) 2017-01-10 US disclosed
US-20150353553-A1 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-12-10 US disclosed
EP-2951180-A1 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS Merck Sharp & Dohme Corp. (US) 2015-12-09 EP disclosed
WO-2014120748-A1 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2014-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353553-A1 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS DDX21, DPYD, NSUN2 TP53 44/4885HSD17B10 3455/4885KMT2A 258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.